10. SEGMENTS

9 Months Ended

12 Months Ended

Dec. 31, 2017

Mar. 31, 2017

Segment Reporting [Abstract]

SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Nine Months Ended December 31,
	2017			2016
Revenues:
Aethlon	$	74,813		$	392,073
ESI		–			–
Total Revenues	$	74,813		$	392,073
Operating Losses:
Aethlon	$	(3,495,189	)	$	(4,478,631	)
ESI		(64,860	)		(115,443	)
Total Operating Loss	$	(3,560,049	)	$	(4,594,074	)
Net Losses:
Aethlon	$	(4,308,807	)	$	(5,497,978	)
ESI		(64,860	)		(115,443	)
Net Loss Before Non-Controlling Interests	$	(4,373,667	)	$	(5,613,421	)
Cash:
Aethlon	$	5,610,061		$	625,531
ESI		738			3,084
Total Cash	$	5,610,799		$	628,615
Total Assets:
Aethlon	$	5,745,031		$	752,578
ESI		5,723			37,019
Total Assets	$	5,750,754		$	789,597
Capital Expenditures:
Aethlon	$	23,705		$	2,961
ESI		–			–
Capital Expenditures	$	23,705		$	2,961
Depreciation and Amortization:
Aethlon	$	27,402		$	16,322
ESI		–			10,043
Total Depreciation and Amortization	$	27,402		$	26,365
Interest Expense:
Aethlon	$	(306,495	)	$	(115,308	)
ESI		–			–
Total Interest Expense	$	(306,495	)	$	(115,308	)

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Fiscal Years Ended March 31,
	2017			2016
Revenues:
Aethlon	$	392,073		$	886,572
ESI		–			–
Total Revenues	$	392,073		$	886,572
Operating Losses:
Aethlon	$	(5,945,293	)	$	(3,953,402	)
ESI		(153,064	)		(431,432	)
Total Operating Loss	$	(6,098,357	)	$	(4,384,834	)
Net Losses:
Aethlon	$	(7,153,662	)	$	(4,527,184	)
ESI		(153,064	)		(431,432	)
Net Loss Before Non-Controlling Interests	$	(7,306,726	)	$	(4,958,616	)
Cash:
Aethlon	$	1,558,667		$	2,114,285
ESI		1,034			9,452
Total Cash	$	1,559,701		$	2,123,737
Total Assets:
Aethlon	$	1,698,249		$	2,475,686
ESI		28,119			53,430
Total Assets	$	1,726,368		$	2,529,116
Capital Expenditures:
Aethlon	$	16,433		$	9,307
ESI		–			–
Capital Expenditures	$	16,433		$	9,307
Depreciation and Amortization:
Aethlon	$	22,370		$	18,943
ESI		10,043			19,581
Total Depreciation and Amortization	$	32,413		$	38,524
Interest Expense:
Aethlon	$	304,330		$	573,782
ESI		–			–
Total Interest Expense	$	304,330		$	573,782